Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

-- Orthocell (ASX:OCC) said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.

The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.

The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.

Orthocell's shares jump nearly 4% in recent trading on Tuesday.

BP塑料公司注销休眠部门；股价下跌3%

根据周一提交给马来西亚证券交易所的文件，BP Plastics（吉隆坡证券交易所代码：BPPLAS）旗下子公司BPPLAS Plantation已被马来西亚公司委员会注销并视为解散。周二午盘交易中，该公司股价下跌约3%。 BPPLAS Plantation此前一直处于停滞状态，没有未来的业务计划，此次解散是公司为精简成本和行政管理而采取的措施之一。该集团表示，此次解散不会对盈利或净资产产生重大影响。

$KLSE:BPPLAS

中国化工集团第一季度利润增长超过8%，营收增长3%。

中国化工集团（SHA:601117）公布第一季度归属于母公司股东的净利润为15.7亿元人民币，较上年同期的14.4亿元人民币增长8.5%。根据周二提交给上海证券交易所的文件，每股收益从0.24元人民币增至0.26元人民币。营收同比增长3.2%，从445亿元人民币增至459亿元人民币。这家油气服务供应商的股价在近期的交易中上涨了2%。

$SHA:601117

Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

相关文章

杰富瑞将完美世界的目标股价从20.60元人民币下调至19.80元人民币，维持“买入”评级。

BP塑料公司注销休眠部门；股价下跌3%

中国化工集团第一季度利润增长超过8%，营收增长3%。